Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 389 matching trials from the live ClinicalTrials.gov search.
Terminated Not applicable Interventional Results available

Intraarticular Corticosteroid Therapy in Perthes Disease.

NCT01026909
Conditions
Legg-Calve Perthes Disease
Interventions
Aristospan 20mg
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
4 Years to 13 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Diabetic Retinopathy
Interventions
triamcinolone acetonide (Kenalog)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs, Lateral Hip Pain
Interventions
Triamcinolone acetate, ReneuRx
Drug · Device
Lead sponsor
Brixton Biosciences, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Sun City, Arizona • Johns Creek, Georgia • New Orleans, Louisiana + 8 more
Conditions
Adhesive Capsulitis, Frozen Shoulder, Adhesive Capsulitis of Shoulder
Interventions
triamcinolone acetonide extended-release injectable suspension
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Advanced Cancer
Interventions
Talking about Cancer (TAC)
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Terminated Not applicable Interventional Results available

Hydrogel Patch for the Treatment of Eczema

NCT00924508
Conditions
Eczema
Interventions
hydrogel patch, Triamcinolone (TAC) 0.1% cream
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Conditions
Osteoarthritis of the Knee
Interventions
FX006, Placebo, TCA IR 40
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 17 more
Conditions
Osteoarthritis of the Knee
Interventions
FX006, TCA IR
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Tucson, Arizona • Duncansville, Pennsylvania
Conditions
Thumb Osteoarthritis
Interventions
Ketorolac, Triamcinolone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Recurrent Adult Hodgkin Lymphoma
Interventions
basiliximab, carmustine, etoposide, cytarabine, melphalan, pharmacological study, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, yttrium Y 90-labeled basiliximab
Biological · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Duarte, California
Conditions
Wound Healing, Granulation Tissue
Interventions
Silver Nitrate, triamcinolone, Silver nitrate + triamcinolone
Drug
Lead sponsor
Francesco Egro
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Drug-Drug Interaction
Interventions
Lorecivivint (LOR), Triamcinolone acetonide (TA)
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Conditions
Dysphagia
Interventions
Dilation, Triamcinolone Injection, Esophagogastroduodenoscopy (EGD)
Procedure · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Completed Not applicable Interventional Results available

Verifying the Effectiveness of the NUsurface® System

NCT02108496
Conditions
Meniscectomy, Osteoarthritis
Interventions
NUsurface® Meniscus Implant, NSAID's and Non-surgical Treatment Options, Intra-Articular Injections with Corticosteroids, Intra-Articular Injections with Hyaluronic Acid (HA)
Device · Drug
Lead sponsor
Phoenix Kinetics
Industry
Eligibility
30 Years to 75 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
9
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Roxbury Crossing, Massachusetts + 6 more
Conditions
Macular Edema, Cystoid, Retinal Vein Occlusion
Interventions
Standard Care, intravitreal triamcinolone injection
Other · Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 3 Interventional Results available

Docetaxel in Breast Cancer

NCT00312208
Conditions
Breast Cancer
Interventions
Docetaxel,doxorubicin, cyclophosphamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Acute Steroid Responsive Dermatoses, Chronic Steroid Responsive Dermatoses
Interventions
Triamcinolone Acetonide spray, Triamcinolone acetonide cream, Alcohol spray
Drug
Lead sponsor
Patel, Rita Vikram, M.D.
Individual
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pudendal Nerve Block in Vaginal Surgery

NCT04198714
Conditions
Nerve Block, Pain, Postoperative, Pelvic Floor Disorders, Pelvic Organ Prolapse, Pudendal Neuralgia, Surgery
Interventions
Pudendal block
Procedure
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

NCT05535738
Conditions
Skin Inflammation, Allergic Contact Dermatitis
Interventions
Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy
Drug · Other · Device + 1 more
Lead sponsor
Wei-Che Ko
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride, Trastuzumab, Carboplatin, Paclitaxel
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Chronic Shoulder Pain
Interventions
Lidocaine 1% Injectable Solution, Triamcinolone Injection, Suprascapular Nerve Block
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Conditions
Full Thickness Rotator Cuff Tear, Rotator Cuff Tendinitis
Interventions
Ketorolac, Marcaine (placebo), Kenalog
Drug
Lead sponsor
Michael Khazzam
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Baltimore, Maryland • Dallas, Texas
Conditions
Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions
ATG dosing platform when combined with standard tacrolimus and mini methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama